Advertisement

Topics

BRIEF-GSK files regulatory submissions in U.S. and Europe for lupus drug

00:44 EDT 23 Sep 2016 | Reuters

* GSK announces regulatory submissions for subcutaneous formulation of Benlysta (Belimumab) for patients with systemic lupus disease

Original Article: BRIEF-GSK files regulatory submissions in U.S. and Europe for lupus drug

NEXT ARTICLE

More From BioPortfolio on "BRIEF-GSK files regulatory submissions in U.S. and Europe for lupus drug"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...